656 related articles for article (PubMed ID: 27259316)
21. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
[TBL] [Abstract][Full Text] [Related]
22. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
23. IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells.
Choi YH; Lim EJ; Kim SW; Moon YW; Park KS; An HJ
J Immunother Cancer; 2019 Jul; 7(1):168. PubMed ID: 31277710
[TBL] [Abstract][Full Text] [Related]
24. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
25. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
[TBL] [Abstract][Full Text] [Related]
26. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
27. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
28. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
29. A simple method for in vitro preparation of natural killer cells from cord blood.
Mu YX; Zhao YX; Li BY; Bao HJ; Jiang H; Qi XL; Bai LY; Wang YH; Ma ZJ; Wu XY
BMC Biotechnol; 2019 Nov; 19(1):80. PubMed ID: 31752805
[TBL] [Abstract][Full Text] [Related]
30. A rapid method for assessment of natural killer cell function after multiple receptor crosslinking.
Al-Hubeshy ZB; Coleman A; Nelson M; Goodier MR
J Immunol Methods; 2011 Mar; 366(1-2):52-9. PubMed ID: 21281644
[TBL] [Abstract][Full Text] [Related]
31. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
33. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
34. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.
Granzin M; Soltenborn S; Müller S; Kollet J; Berg M; Cerwenka A; Childs RW; Huppert V
Cytotherapy; 2015 May; 17(5):621-32. PubMed ID: 25881519
[TBL] [Abstract][Full Text] [Related]
35. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
36. Effects of prolactin and cortisol on natural killer (NK) cell surface expression and function of human natural cytotoxicity receptors (NKp46, NKp44 and NKp30).
Mavoungou E; Bouyou-Akotet MK; Kremsner PG
Clin Exp Immunol; 2005 Feb; 139(2):287-96. PubMed ID: 15654827
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC.
Balsamo M; Manzini C; Pietra G; Raggi F; Blengio F; Mingari MC; Varesio L; Moretta L; Bosco MC; Vitale M
Eur J Immunol; 2013 Oct; 43(10):2756-64. PubMed ID: 23913266
[TBL] [Abstract][Full Text] [Related]
38. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells.
Nham T; Poznanski SM; Fan IY; Vahedi F; Shenouda MM; Lee AJ; Chew MV; Hogg RT; Lee DA; Ashkar AA
J Immunother; 2018; 41(2):64-72. PubMed ID: 29189387
[TBL] [Abstract][Full Text] [Related]
39. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
40. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
